Assessment And Treatment Of Depression And Anxiety: Integrating Psychopharmacology And Psychotherapy 2021 (Videos)

Assessment And Treatment Of Depression And Anxiety: Integrating Psychopharmacology And Psychotherapy 2021 (Videos)

Regular price€25,00
/
Tax included. Shipping calculated at checkout.

  • Free Shipping on orders over 45$
  • In stock, ready to ship
  • Inventory on the way

Assessment And Treatment Of Depression And Anxiety: Integrating Psychopharmacology And Psychotherapy 2021 (Videos)


In addition to highlighting emerging strategies in the assessment and treatment of major depression and bipolar illness, this online CME course defines approaches to mood and anxiety disorders, including psychodynamic psychotherapy, cognitive and behavioral therapy, interpersonal psychotherapy for depression and other psychotherapeutic approaches.

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy also addresses comorbid conditions such as Axis II personality disorders, management of patients with medical conditions, management of the geriatric patient, and more. It’s psychiatry CME that offers insight into:
  • Issues around the choice of specific antidepressants, mood stabilizers and anti-anxiety medications
  • Psychopharmacologic management of the treatment resistant patient
  • Recent developments in neuropsychiatry, including brain imaging and therapeutic stimulation techniques
  • Therapeutic efficacy and risks associated with ketamine administration
  • Obsessive-compulsive disorders including skin-picking, trichotillomania and body dysmorphic
  • Management of anxiety in patients vulnerable to abuse of alcohol
  • And more…

Learning Objectives


Upon completion of this activity, participants will be better able to:
  • Evaluate emerging strategies in the use of psychotropic medications in the treatment of major depression and anxiety disorders and integrate psychopharmacologic treatments into psychotherapy strategies in treating depressed and anxious patents
  • Describe strategies for the psychopharmacological and psychotherapeutic management of treatment resistant depression
  • Summarize the emerging role of ketamine in the treatment of major depression and suicidal behavior
  • Explore the role of novel enhancements to treatment of mood disorders including omega 3 fatty acids, 1 methylfolate and zinc
  • Discuss the role of electroconvulsive therapy and Transcranial Magnetic Stimulation in treatment resistant depressive disorders
  • Examine new developments in the treatment of depression in bipolar patients with a focus on newer medications including lurasidone and cariprazine
  • Identify an evidence-based approach to suicide risk assessment and prevention of suicide
  • Appreciate the role of lithium carbonate in combination with other mood stabilizing agents
  • Give examples of recent developments in psychotherapeutic approaches to treating Bipolar patients, including cognitive, behavioral and expressive psychotherapy techniques
  • Integrate psychodynamic assessment, psychotherapy and psychopharmacology into management of depression and anxiety disorders
  • Assess the role of Cognitive Behavioral Therapy (CBT) in the treatment of depression and anxiety disorders
  • Compare recent developments in the implementation of CBT, including Commitment and Acceptance Therapy and inclusion of exposure therapy in CBT
  • Report on the latest applications for computer- based treatment of OCD and other anxiety disorders
  • Describe new psychopharmacological and psychotherapeutic techniques in the treatment of PTSD including exposure and response prevention and virtual reality techniques utilized to treat PTSD secondary to exposure to combat
  • Formulate an integrated psychopharmacological and psychotherapeutic approach to personality-disordered patients in the borderline and severely narcissistic spectrum presenting with depression and anxiety
  • Manage anxiety disorders in patients vulnerable to alcohol abuse and psychological dependence on marijuana, including the use of non-benzodiazepine anti-anxiety agents such as pregabalin and buspirone
  • Formulate strategies for treating patients with marijuana abuse disorder, including discussion of newly emerging psychopharmacological and psychotherapeutic techniques

Target Audience


This educational activity was designed for health professionals in the fields of psychiatry, psychology, nursing, social work, counseling, medicine, pediatrics, and surgery.

TOPICS / SPEAKERS

All lectures by Russell G. Vasile, MD

Assessment and Treatment of Major Depressive Disorder

Psychopharmacologic Management of Bipolar Disorder Emerging Perspectives

Anxiety Disorders- Assessment and Pharmacotherapy

Suicide Assessment and Prevention, Psychotherapy of Depression and Perspectives on Personality Disorder

Assessment and Management of Depression in the Elderly and Brain Imaging

Date Of Original Release: October 15, 2021
Termination Date: January 31, 2024
Estimated Time To Complete The Activity: 13.00 Hours

- Orders under 45$ will have a shipping charge of a flat rate of 15$.

-Orders over 45$ will have Free Shipping.

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Testimonials

★★★★★


“I find the taste of Moringa tea to be very refreshing and it definitely gives me a feeling of ‘wellness’. I appreciate the ethics of the company. Am looking forward to trying the cream”

Elain
★★★★★


”I love knowing that everything is 100% chemical-free and tested in Canada. I also respect the sustainable farming approach that supports both Canada and Ethiopia.”

Alycia
★★★★★

Since I drink Moringa Tea I feel so much better. My mouth was always so dry but since I drink this tea I have so much saliva I drool.

I cannot believe how much it has helped me with my breathing. I love it. I even eat all the leaves - Thank you for introducing me to this herbal tea. I'm 85 years old.

Richard Dorge
Winnipeg, MB

Recently viewed